Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 9/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | WNT1 | P04628 | 2/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955600 | 0.84 | KDM4E (0.41) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL12075527 | 0.83 | BRD4 (0.41) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL17581961 | 0.80 | BRD4 (0.36) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL2687071 | 0.78 | KMT2A (0.52) | BRD4 | |
| SCHEMBL17109407 | 0.77 | CCR1 (0.59) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL22230154 | 0.77 | PCSK9 (0.43) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL23999759 | 0.77 | CCR1 (0.59) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL13872400 | 0.77 | HSD17B1 (0.44) | KDM4EKDM4AKDM5CKDM4CKDM2A | |
| SCHEMBL9143504 | 0.77 | KDR (0.50) | KDM4EKDM5CFLT3 | |
| SCHEMBL12620351 | 0.77 | FLT3 (0.54) | KDM4EKDM4AKDM5CKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259721-A1 | CELL LINES | AARS1, LARS1, IARS1 | KDM4E 2025/4885KDM4A 2651/4885KDM5C 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.